0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Presidential Address | 
Ashby C. Moncure, MD
Arch Surg. 2001;136(4):376-382. doi:10.1001/archsurg.136.4.376.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Neurology
Editorial  | 
Perspectives on Safety and Efficacy—The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis
Edward R. Hammond, MD, PhD, MPH
JAMA Neurology
Original Investigation  | 
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study
Ludwig Kappos, MD; David K. B. Li, MD; Olaf Stüve, MD; et al.
JAMA Neurology
Editorial  | 
Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis Are There Lessons to Be Learned?
Rhonda Voskuhl, MD
JAMA Neurology
Original Investigation  | 
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
Stacy Ellen Hatcher, BS; Emmanuelle Waubant, MD, PhD; Bardia Nourbakhsh, MD; et al.